Concepedia

Masanori Yokono

MY

10

Publications

1.1K

Citations

10

H-Index

2006

Active since

Affiliations

Astellas Pharma (Japan)(Current)

Astellas Pharma (Netherlands)

Kissei Pharmaceutical (Japan)

Masanori Yokono is an author at Astellas Pharma (Japan) specializing in pharmacology, medicine, and metabolic syndrome.

ORCID

Top concepts

Publications per year

2006–2019

10

Publications

10

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 305 citations

, , +10

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 190 citations · Full text

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono et al. · Journal of Pharmacological Sciences · 2016 · 144 citations · Full text

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Journal of Pharmacy and Pharmacology · 2014 · 122 citations

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2011 · 106 citations

, , +7

Rows per page

1–5 of 10